Biosimilar rhG-CSFs: How similar are they?

Targeted Oncology

Volumn 7, Issue SUPPL.1, 2012, Pages

  Gravel, Patricia ^a   Naik, Aarti ^a   Le Cotonnec, Jean Yves ^a  

^a Triskel Integrated Services SA   (Switzerland)

Author keywords

Biosimilars; Filgrastim; Neupogen ; Nivestim ; rhG CSF; XM02; Zarzio

Indexed keywords

BIOSIMILAR AGENT; EP 2006; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLD 108; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; XM 02;

BIOEQUIVALENCE; BIOTECHNOLOGY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; EUROPE; HUMAN; IMMUNOGENICITY; NONHUMAN; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE;

BIOLOGICAL AGENTS; EUROPE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; RECOMBINANT PROTEINS; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION;

EID: 84857894949     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0187-4     Document Type: Review

References (66)

1. R&D Pipeline news (2010) Top 30 Biologics 2010. March 3, 2011. Available from www.pipelinereview.com
2. Aapro M, Cornes P, Abraham I (2011) Comparative costefficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract. doi:10.1177/1078155211407367
3. Stewart A, Aubrey P, Belsey J (2010) Addressing the health technology assessment of biosimilar pharmaceuticals. Curr Med Res Opin 26:2119-2126
4. Arakawa T, Prestrelski SJ, Narhi LO, Boone TC, Kenney WC (1993) Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J Protein Chem 12:525-531 (Pubitemid 24008503)
5. Nagata S (1994) Granulocyte colony stimulating factor and its receptor. In: Thomson AW (ed) The cytokine handbook, 2nd. Academic, London, pp 371-385
6. Herman AC, Boone TC, Lu SH (1996) Characterization, formulation, and stability of Neupogen (filgrastim), a recombinant human granulocyte-colony stimulating factor. In: Pearlman R, Wang JY (eds) Formulation, Characterization, and Stability of Protein Drugs. Plenum Press, New York
7. Oheda M, Hase S, Ono M, Ikenaka T (1988) Structures of the sugar chains of recombinant human granulocyte-colony-stimulating factor produced by Chinese hamster ovary cells. J Biochem 103:544-546 (Pubitemid 18090075)
8. Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8-32
9. Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use, as amended by Directive 2004/27/EC of 31 March 2004. Available from: http://ec.europa.eu/ health/documents/eudralex/vol-1/index-en.htm
10. Part II of the Annex I of Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use, as amended by Directive 2003/63/EC of 25 June 2003. Available from: http://ec.europa.eu/health/documents/eudralex/vol-1/index-en.htm
11. Schellekens H (2005) Follow-on biologics: challenges of the "next generation". Nephrol Dial Transplant 20(Suppl 4):iv31-iv36
12. World Health Organization Expert Committee on Biological Standardization (2009) Guidelines on evaluation of similar biotherapeutic products (SBPs). Available from: http://www.who.int
13. Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER) (1996) Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. Available from http://www.fda.gov
14. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (2004) ICH Q5E: Comparability of biotechnological/biological products subject to changes in their manufacturing process. Available from: http://www.ich.org
15. European Medicines Agency (2003) EU Guideline on comparability of medicinal products containing biotechnology-derived proteins as active substances: Quality issues. EMEA/CHMP/BWP/3207/00/Rev. 1. Available from: http://www.ema.europa.eu
16. McCamish M, Woollett G (2011) Worldwide experience with biosimilar development. MAbs 3:209-217
17. Gravel P, Le Cotonnec J-Y (2011) Qu'est-ce qu'un biosimilaire? Jusqu'où va la similarité? Oncologie 13:183-190
18. Le Cotonnec JY, Lawny F (2009) L'importance de la qualité en biotechnologie: le cas du 1er biosimilaire de l'EPO. Nephrol Ther 5 Spec No1:10-15
19. European Medicines Agency (2008) Zarzio® EPAR: CHMP Assessment Report (EMEA/CHMP/651339/2008). Available from: http://www.ema.europa.eu
20. European Medicines Agency (2008) Filgrastim Hexal® EPAR: CHMP Assessment Report (EMEA/CHMP/651324/2008). Available from: http://www.ema. europa.eu
21. European Medicines Agency (2008) Biograstim® EPAR: Assessment report (EMEA/494720/2008). Available from: http://www.ema.europa.eu
22. European Medicines Agency (2008) Filgrastim ratiopharm® EPAR: Assessment report (EMEA/501324/2008). Available from: http://www.ema.europa.eu
23. European Medicines Agency (2008) Ratiograstim® EPAR: Assessment report (EMEA/502481/2008). Available from: http://www.ema.europa.eu
24. European Medicines Agency (2008) Tevagrastim® EPAR: Assessment report (EMEA/503293/2008). Available from: http://www.ema.europa.eu
25. European Medicines Agency (2010) Nivestim® EPAR: CHMP assessment report (EMA/262762/2010). Available from: http://www.ema.europa.eu
26. Skrlin A, Radic I, Vuletic M, Schwinke D, Runac D, Kusalic T, Paskvan I, Krsic M, Bratos M, Marinc S (2010) Comparison of the physicochemical properties of a biosimilar filgrastim with those of reference filgrastim. Biologicals 38:557-566
27. Sorgel F, Lerch H, Lauber T (2010) Physicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference product. BioDrugs 24:347-357
28. Roskos L, Cheung E, Vincent M (1988) Pharmacology of filgrastim (r-metHuG-CSF). In: Morstyn T, Dexter T, Foote E (eds) Filgrastim (r-metHuG-CSF) in clinical practice, 2nd edn. Marcel Dekker, New York, pp 51-71
29. Korbling M (1998) In vivo expansion of the circulating stem cell pool. Stem Cells 16(Suppl 1):131-138
30. Kronenwett R, Martin S, Haas R (2000) The role of cytokines and adhesion molecules for mobilization of peripheral blood stem cells. Stem Cells 18:320-330
31. European Medicines Agency (2006) Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte-colony stimulating factor (EMEA/CHMP/BMWP/31329/2005). Available from: http://www.ema.europa.eu
32. Gascon P, Fuhr U, Sorgel F, Kinzig-Schippers M, Makhson A, Balser S, Einmahl S, Muenzberg M (2010) Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 21:1419-1429
33. Lubenau H, Sveikata A, Gumbrevicius G, Macijauskiene J, Fokas V, Kazlauskas S, Janulionis V (2009) Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers. Int J Clin Pharmacol Ther 47:275-282
34. Waller CF, Bronchud M, Mair S, Challand R (2010) Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 89:927-933
35. Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K (2009) Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs 23:43-51
36. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del GA (2009) XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 50:374-379
37. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, del GA (2009) XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 4:736-740
38. Waller CF, Bronchud M, Mair S, Challand R (2010) Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 89:971-978
39. Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R (2010) A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 33:504-511
40. Lefrere F, Brignier AC, Elie C, Ribeil JA, Bernimoulin M, Aoun C, Dal CL, Delarue R, Hermine O, Cavazzana-Calvo M (2011) First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Ther 28:304-310
41. Publicover A, Richardson DS, Hill K, Hurlock C, Casey P, Newman J, Orchard KH (2010) Use of biosimilar GCSF for peripheral blood progenitor cell mobilisation prior to autologous stem cell transplantation: a single-centre experience. Bone Marrow Transplant 45(suppl 2):S158
42. European Group for Blood and Marrow Transplantation (EBMT) (2009) Position statement: biosimilar granulocyte-colony stimulating factor (G-CSF) for stem cell mobilization in related and unrelated donors. Available from: www.ebmt.org.
43. Shaw BE, Confer DL, Hwang WY, Pamphilon DH, Pulsipher MA (2011) Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 96:942-947
44. Gratwohl A, Baldomero H, Schwendener A, Rocha V, Apperley J, Frauendorfer K, Niederwieser D (2009) The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant 43:275-291
45. Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ (2006) Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 134:517-525 (Pubitemid 44141718)
46. Amgen (2010) US product label for Zarzio®. Available from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm
47. Jelkmann W (2010) Biosimilar epoetins and other "follow- on"biologics: update on the European experiences. Am J Hematol 85:771-780
48. Niederwieser D, Schmitz S (2011) Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 86:277-288
49. Biologics Price Competition and Innovation Act (BPCIA) of 2009. Sections 7001-7003 of the Patient Protection and Affordable Care Act (PPACA) (Public Law No. 111-148). Available from: http://www.fda.gov
50. Fuchs VR, Milstein A (2011) The $640 billion question-why does cost-effective care diffuse so slowly? N Engl J Med 364:1985-1987
51. Young PL, Olsen L (2010) The healthcare imperative: Lowering costs and improving outcomes: Workshop series summary. Available from: http://www.nap.edu/catalog/12750.html. Accessed July 14, 2011.
52. OECD (2011) www.oecd.org/health/healthdata. Accessed July 14, 2011.
53. Eurostat (2011) http://epp.eurostat.ec.europa.eu/portal/page/portal/ health/public-health. Accessed July 14, 2011.
54. EvaluatePharma (2009) http://www.evaluatepharma.com/Universal/View.aspx? type=Story&id=188700§ionID=&isEPVantage=yes. Accessed July 14, 2011.
55. European Medicines Agency (2005) Guideline on similar biological medicinal products (CHMP/437/04). Available from: http://www.ema.europa.eu
56. European Medicines Agency (2006) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Quality issues (EMEA/CHMP/BWP/49348/2005). Available from: http://www.ema.europa.eu
57. European Medicines Agency (2006) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005). Available from: http://www.ema.europa.eu
58. European Medicines Agency (2006) Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant human soluble insulin (EMEA/CHMP/BMWP/32775/ 2005). Available from: http://www.ema.europa.eu
59. European Medicines Agency (2006) Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: Non-clinical and clinical issues. Guidance on similar medicinal products containing somatropin (EMEA/CHMP/BMWP/94528/2005). Available from: http://www.ema.europa.eu
60. European Medicines Agency (2009) Reflection paper: Non-clinical & clinical development of similar medicinal products containing recombinant interferon alfa (EMEA/CHMP/BMWP/102046/2006). Available from: http://www.ema.europa.eu
61. European Medicines Agency (2009) Guideline on non-clinical and clinical development of similar biological medicinal products containing low-molecular-weight heparins (EMEA/CHMP/BMWP/118264/2007). Available from: http://www.ema.europa.eu
62. European Medicines Agency (2010) Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision) (EMEA/CHMP/BMWP/301636/2008 Corr.). Available from: http://www.ema.europa.eu
63. European Medicines Agency (2010) Draft guideline on similar biological medicinal products containing monoclonal antibodies (EMA/CHMP/BMWP/403543/2010). Available from: http://www.ema.europa.eu
64. European Medicines Agency (2011) Draft guideline on similar biological medicinal product containing interferon beta (EMA/CHMP/BMWP/652000/2010). Available from: http://www.ema.europa.eu
65. European Medicines Agency (2010) Draft guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH) (EMA/CHMP/BMWP/671292/ 2010). Available from: http://www.ema.europa.eu
66. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H (2008) XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 8:332